Pay in 4 interest-free payments of $5.33 Learn more
Ships within 48 hours · Estimated delivery Aug 18 - Aug 23
Some plans cover it, some dont, and some cover it initially but drop coverage after a set period
J Proteome Res 14(6):26062616
Coskuns research contributions span the entire development arc of GLP3 : Discovery and initial characterization of GLP3 s triple-receptor agonist properties and pharmacological profile Preclinical studies establishing proof-of-mechanism in mouse models and in vitro receptor systems Design and medical oversight of phase 1b and phase 2 clinical trials in type 2 diabetes and obesity Investigation of GLP3 s effects on gastric emptying and mechanistic studies of weight loss Contribution to over 168 peer-reviewed publications in metabolic disease research with citation impact exceeding 8,700 citations His work extends beyond GLP3 to include fundamental contributions to the development of GLP2 and advancement of incretin-based therapeutics more broadly
Profit before tax rose by 3% to 130.5bn kroner
